When initial therapy is ineffective in patients with HABP/VABP or cSSSI due to S. aureus, choose VIBATIV. The once-daily antibiotic infusion with a dual mechanism of action indicated for MRSA and MSSA
Proven to treat HABP/VABP (including MRSA or MSSA) or cSSSI1
VIBATIV for HABP/VABP
Learn about VIBATIV for the treatment of hospital–acquired and ventilator–associated pneumonia, including MRSA and MSSA.
VIBATIV for cSSSI
Learn about VIBATIV for the treatment of complicated skin and skin structure infections.
